CytoMed Therapeutics Limited (NASDAQ:GDTC – Get Free Report) shares fell 13.7% during mid-day trading on Tuesday . The company traded as low as $2.77 and last traded at $2.96. 313,428 shares changed hands during trading, a decline of 89% from the average session volume of 2,783,089 shares. The stock had previously closed at $3.43.
Wall Street Analyst Weigh In
Separately, Benchmark reissued a “speculative buy” rating and issued a $5.00 price target on shares of CytoMed Therapeutics in a report on Thursday, October 10th.
View Our Latest Report on GDTC
CytoMed Therapeutics Price Performance
About CytoMed Therapeutics
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity.
Read More
- Five stocks we like better than CytoMed Therapeutics
- Buy P&G Now, Before It Sets A New All-Time High
- MercadoLibre: Latin America’s Digital Titan Just Got Cheaper
- 3 Best Fintech Stocks for a Portfolio Boost
- Breaking Down Pegasystems, A Wedbush Top AI Pick for 2025
- Market Cap Calculator: How to Calculate Market Cap
- Shutterstock and Getty: A $3.7 Billion Visual Content Giant
Receive News & Ratings for CytoMed Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoMed Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
